Aliases & Classifications for Tic Disorder

MalaCards integrated aliases for Tic Disorder:

Name: Tic Disorder 12 15 71
Behavioral Tic 71
Tics 6

Classifications:



External Ids:

Disease Ontology 12 DOID:2769
ICD9CM 34 307.20
MeSH 44 D013981
SNOMED-CT 67 155005001
ICD10 32 F95 F95.9
UMLS 71 C0040188 C0278076

Summaries for Tic Disorder

Disease Ontology : 12 A specific developmental disorder that is characterized by the persistent presence of involuntary brief movements or sounds occuring intermittently and unpredictably out of a background of normal motor activity.

MalaCards based summary : Tic Disorder, also known as behavioral tic, is related to chronic tic disorder and obsessive-compulsive disorder, and has symptoms including ataxia, tremor and myoclonus. An important gene associated with Tic Disorder is DRD4 (Dopamine Receptor D4), and among its related pathways/superpathways are Monoamine GPCRs and Methylphenidate Pathway, Pharmacodynamics. The drugs Sevoflurane and Propofol have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and prostate, and related phenotypes are behavior/neurological and integument

Wikipedia : 74 Tic disorders are defined in the Diagnostic and Statistical Manual of Mental Disorders (DSM) based on... more...

Related Diseases for Tic Disorder

Diseases in the Tic Disorder family:

Chronic Tic Disorder Transient Tic Disorder

Diseases related to Tic Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 278)
# Related Disease Score Top Affiliating Genes
1 chronic tic disorder 32.7 SLITRK5 SLITRK1 NRXN1 IMMP2L DRD4 DLGAP3
2 obsessive-compulsive disorder 31.4 TPH2 SLITRK5 SLITRK1 SLC6A3 HTR2A DRD4
3 gilles de la tourette syndrome 31.0 SLITRK1 SLC6A3 PVALB NRXN1 NLGN4X MIR24-1
4 attention deficit-hyperactivity disorder 30.7 TPH2 SLC6A3 PRODH NLGN4X IMMP2L HTR2A
5 tardive dyskinesia 30.7 HTR2A DRD4 DRD2
6 stuttering 30.7 SLC6A3 PVALB DRD2 CNTNAP2
7 conduct disorder 30.6 SLC6A3 DRD4 DRD2
8 movement disease 30.6 SLC6A3 PRODH PNKD DRD2
9 oppositional defiant disorder 30.5 TPH2 SLC6A3 HTR2A DRD4 DRD2
10 social phobia 30.4 PRODH HTR2A DRD2
11 generalized anxiety disorder 30.4 SLC6A3 HTR2A DRD2
12 paroxysmal dystonia 30.3 SLC6A3 PVALB PNKD
13 alcohol use disorder 30.2 SLC6A3 HTR2A DRD2
14 echolalia 30.1 PRODH NRXN1 NLGN4X CNTNAP2
15 dystonia 30.1 SLC6A3 PVALB PNKD HTR2A DRD2
16 trichotillomania 30.1 SLITRK5 SLITRK1 MIR24-1 DRD4 DLGAP3
17 mood disorder 30.1 TPH2 SLC6A3 PRODH HTR2A DRD4 DRD2
18 anxiety 30.1 TPH2 SLC6A3 PRODH HTR2A DRD4 DRD2
19 cyclothymic disorder 30.1 HTR2A DRD4 DRD2
20 migraine with or without aura 1 30.0 SLC6A3 HTR2A DRD4 DRD2
21 personality disorder 30.0 TPH2 SLC6A3 HTR2A DRD4 DRD2
22 alcohol dependence 30.0 TPH2 SLC6A3 HTR2A DRD4 DRD2
23 choreatic disease 30.0 SLC6A3 PVALB PNKD DRD2 CNTNAP2
24 separation anxiety disorder 30.0 SLC6A3 DRD4
25 oculogyric crisis 29.9 PRODH HTR2A
26 dyslexia 29.9 SLC6A3 DRD4 DRD2 CNTNAP2
27 migraine with aura 29.9 SLC6A3 HTR2A DRD2
28 panic disorder 29.8 TPH2 SLC6A3 HTR2A DRD4 DRD2
29 motor neuron disease 29.8 PVALB PRODH MIR24-1 HTR2A
30 substance abuse 29.8 SLC6A3 PRODH HTR2A DRD4 DRD2
31 fragile x syndrome 29.7 PVALB PRODH NRXN1 NLGN4X MIR24-1 DLGAP3
32 autism 29.7 TPH2 SLC6A3 PRODH NRXN1 NLGN4X IMMP2L
33 major depressive disorder 29.6 TPH2 SLC6A3 PVALB HTR2A DRD4 DRD2
34 speech disorder 29.6 SLC6A3 PVALB PRODH NRXN1 DRD2 CNTNAP2
35 mental depression 29.6 TPH2 SLC6A3 PRODH MIR24-1 HTR2A DRD4
36 autism spectrum disorder 29.5 TPH2 SLC6A3 PRODH NRXN1 NLGN4X MIR140
37 schizophrenia 29.4 TPH2 SLC6A3 PVALB PRODH NRXN1 NLGN4X
38 psychotic disorder 29.4 TPH2 SLC6A3 PVALB PRODH NRXN1 MIR24-1
39 pervasive developmental disorder 29.4 PVALB PRODH NRXN1 NLGN4X MIR24-1 MIR140
40 bipolar disorder 29.2 TPH2 SLC6A3 PVALB PRODH NRXN1 HTR2A
41 transient tic disorder 11.6
42 chorea, benign hereditary 11.0
43 47,xyy 10.9
44 pediatric acute-onset neuropsychiatric syndrome 10.9
45 ceroid lipofuscinosis, neuronal, 4b, autosomal dominant 10.8
46 mcleod syndrome 10.8
47 convulsions, familial infantile, with paroxysmal choreoathetosis 10.8
48 neurodegeneration with brain iron accumulation 6 10.8
49 adult neuronal ceroid lipofuscinosis 10.8
50 pediatric autoimmune neuropsychiatric disorders associated with streptococcus infections 10.8

Graphical network of the top 20 diseases related to Tic Disorder:



Diseases related to Tic Disorder

Symptoms & Phenotypes for Tic Disorder

UMLS symptoms related to Tic Disorder:


ataxia, tremor, myoclonus, dystonia, athetosis, symptoms, synkinesis, recurrent muscle twitches (symptom), tic, motor, tic, gestural, tic, transient, tic, vocal

MGI Mouse Phenotypes related to Tic Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.13 CNTNAP2 DLGAP3 DRD2 DRD4 HDC HSPD1
2 integument MP:0010771 9.85 CNTNAP2 DLGAP3 DRD2 HDC HSPD1 IMMP2L
3 nervous system MP:0003631 9.8 CNTNAP2 DLGAP3 DRD2 DRD4 HDC HSPD1
4 taste/olfaction MP:0005394 8.92 CNTNAP2 DRD2 SLC6A3 TPH2

Drugs & Therapeutics for Tic Disorder

Drugs for Tic Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 133)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
2
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
3
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
4
Ticagrelor Approved Phase 4 274693-27-5 9871419
5
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
6
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
7
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
8
Clonidine Approved Phase 4 4205-90-7 2803
9
Levetiracetam Approved Phase 4 102767-28-2 441341
10
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
11
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
12
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
13
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
14
Ondansetron Approved Phase 4 99614-02-5 4595
15
Galantamine Approved Phase 4 357-70-0 9651
16
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
17 Liver Extracts Phase 4
18 Anesthetics, Inhalation Phase 4
19 Platelet Aggregation Inhibitors Phase 4
20 Anesthetics, Intravenous Phase 4
21 Anesthetics, General Phase 4
22 Purinergic P2Y Receptor Antagonists Phase 4
23 Dopamine Agents Phase 4
24 Dopamine Antagonists Phase 4
25 Protective Agents Phase 4
26 Anticonvulsants Phase 4
27 Excitatory Amino Acid Antagonists Phase 4
28 Neuroprotective Agents Phase 4
29 Dopamine agonists Phase 4
30 Serotonin 5-HT1 Receptor Agonists Phase 4
31 Serotonin Receptor Agonists Phase 4
32 Antidepressive Agents Phase 4
33 Antibiotics, Antitubercular Phase 4
34 Anti-Infective Agents Phase 4
35 Anti-Bacterial Agents Phase 4
36 Adrenergic Agonists Phase 4
37 Antihypertensive Agents Phase 4
38 Adrenergic alpha-Agonists Phase 4
39 Sympatholytics Phase 4
40 Analgesics Phase 4
41 Adrenergic Agents Phase 4
42 Anesthetics Phase 4
43 Hypnotics and Sedatives Phase 4
44 Analgesics, Non-Narcotic Phase 4
45 Pharmaceutical Solutions Phase 4
46 Hormones Phase 4
47 Tocolytic Agents Phase 4
48 Calcium, Dietary Phase 4
49 calcium channel blockers Phase 4
50 Anti-Arrhythmia Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 93)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Long Term Postoperative Cognitive Dysfunction After Laparoscopic Cholecystectomy in the Elderly Patients Unknown status NCT02301676 Phase 4 Sevoflurane;propofol
2 Comparison of TIcagrelor and Clopidogrel in Patients With Coronary Artery diseaSe and Type 2 Diabetes Mellitus (TICS-DM): a Randomized Pharmacodynamic Study Unknown status NCT02457130 Phase 4 Ticagrelor;Clopidogrel
3 Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission Completed NCT01018056 Phase 4 D-serine;Riluzole;Placebo
4 Comparison of Keppra and Clonidine in the Treatment of Tics in Children With Tourette Syndrome Completed NCT00370838 Phase 4 Levetiracetam;Clonidine
5 Guanfacine in Children With Tic Disorders: A Multi-site Study Completed NCT01547000 Phase 4 placebo;extended-release guanfacine (Intuniv)
6 Comparison Between Magnesium Sulfate and Dexmedetomidine in Controlled Hypotension During Functional Endoscopic Sinus Surgery: A Double-blind, Randomized Clinical Trial Completed NCT01956981 Phase 4 Magnesium Sulfate;Dexmedetomidine
7 Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT00241176 Phase 4 Aripiprazole
8 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
9 Effects of Ondansetron in Obsessive-compulsive and Tic Disorders Recruiting NCT03239210 Phase 4 Ondansetron;Placebo
10 Pilot Examination of Galantamine in the Management of Tic Disorders Terminated NCT00226824 Phase 4 galantamine
11 A 3-arm Phase III Study of 5LGr, Tiapride or Placebo in Pediatric Patients With Tic Disorder Completed NCT01501695 Phase 3 5LGr;tiapride;placebo
12 A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder Completed NCT00706589 Phase 3 aripiprazole;placebo
13 Behavior Therapy for Children With Chronic Tic Disorders Completed NCT00218777 Phase 2, Phase 3
14 A Randomized Multi-centre Double-blind Placebo Controlled Trial to Demonstrate the Efficacy and Safety of Nabiximols in the Treatment of Adults With Chronic Tic Disorders Completed NCT03087201 Phase 3 nabiximols;placebo
15 A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated With Tourette Syndrome Completed NCT03571256 Phase 3 TEV-50717;Placebo
16 An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727713 Phase 3 Aripiprazole
17 A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-Dose Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder Completed NCT01727700 Phase 3 Aripiprazole;Placebo
18 Effect of Preventive Sodium Lactate Infusion on Intracranial Hypertension in Severe Trauma Tic Brain Injury Completed NCT00995683 Phase 2, Phase 3 half molar sodium lactate;isotonic sodium chloride
19 Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): An Efficacy Study Not yet recruiting NCT04387305 Phase 3 Tranexamic acid injection
20 Behavior Therapy and Psychosocial Treatment for Tourette Syndrome and Chronic Tic Disorder Completed NCT00231985 Phase 2
21 Voice Over Internet Protocol Delivered Behavior Therapy for Tourette Syndrome Completed NCT02247206 Phase 2
22 A Randomized, Placebo-Controlled Study of ABX-1431 in Adult Patients With Tourette Syndrome or Chronic Motor Tic Disorder Completed NCT03625453 Phase 2 ABX-1431;Placebo
23 Fecal Microbial Transplantation and Fiber Supplementation in Subjects With Obesity and Metabolic Syndrome Completed NCT03727321 Phase 2
24 A Trial of Prophylaxis for the PANDAS Subgroup Completed NCT00001359 Phase 2 Penicillin or Placebo
25 A Multicenter Double-blind, Placebo Controlled, Randomized, Pilot Trial to Assess the Efficacy of Pre-hospital Administration of Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC) Completed NCT01475344 Phase 1, Phase 2 Human Fibrinogen Concentrate;Placebo
26 Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): A Pilot and Feasibility Study Completed NCT02840097 Phase 2 Tranexamic Acid;Placebo
27 Developing Effective Response Inhibition Training for Symptom Relief in Tourette Syndrome Completed NCT01440023 Phase 1
28 A Randomized, Placebo-Controlled, Single-Dose Crossover Study of ABX-1431 HCl in Adult Patients With Tourette Syndrome (TS) and Chronic Motor Tic Disorder Completed NCT03058562 Phase 1 ABX-1431;Placebo Comparator;ABX-1431
29 Open-label, Randomized, Single Dose, 4period, Replicated, Cross-over Trial to Assess the Bioequivalence of Feniramidol HCl 400 mg Film Tablet in Comparison With Cabral 400 mg Film Tablet in Healthy Male Subjects Under Fed Conditions Completed NCT04639869 Phase 1 Phenyramydol HCl 400 mg Film Tablet;Cabral 400 mg Film Tablet
30 Comparative, Randomized, Two -Period, Two-treatment, Two -Sequence, Open Label, Crossover Bioequivalence Pilot Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fed Conditions. Completed NCT02185846 Phase 1 DYNABAC 250 MG ENTERIC COATED TABLET;DIRITHROMYCIN 500 MG ENTERIC COATED TABLET
31 Comparative, Randomized, Two -Period, Two-treatment, Two -Sequence, Open Label, Crossover Bioequivalence Pilot Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions. Completed NCT02185833 Phase 1 DIRITHROMYCIN 500 MG ENTERIC COATED TABLET;DYNABAC 250 MG ENTERIC COATED TABLET
32 Comparative, Randomized, Three -Period, Two-treatment, Three -Sequence, Open Label, Semi-replicate Crossover Bioequivalence Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fed Conditions Completed NCT02237807 Phase 1 DIRITHROMYCIN 500 MG ENTERIC COATED TABLET;DYNABAC 250 MG ENTERIC COATED TABLET
33 Comparative, Randomized, Three -Period, Two-treatment, Three -Sequence, Open Label, Semi-replicate Crossover Bioequivalence Study of Dirithromycin 500 mg Enteric Coated Tablet (One Tablet) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) Versus Dynabac 250 mg Enteric Coated Tablet (Two Tablets) of (Abdi İbrahim İlaç San. Ve Tic. A. Ş., Turkey) in Healthy Subjects Under Fasting Conditions. Completed NCT02237768 Phase 1 DIRITHROMYCIN 500 MG ENTERIC COATED TABLET;DYNABAC 250 MG ENTERIC COATED TABLET
34 Comparative, Randomized, Two-period, Two-treatment, Two-sequence, Single Dose, Open-label, Crossover Bioequivalence Study of FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET (One Tablet) of (Sanovel İlaç San. ve Tic. A.Ş., İstanbul / Türkiye) Versus ANTADYS® Flurbiprofen 100 mg Comprimé Pelliculé (One Film-coated Tablet) of (LaboratoireThẻramex 6, Avenue Albert II- BP.59 98007 MONACO Cedex) and PEPCID® (Famotidine) 20 mg Tablets, USP (One Tablet) of (Marathon Pharmaceuticals, LLC USA) in Healthy Subjects Under Fasting Conditions Completed NCT01910090 Phase 1 FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET;ANTADYS® 100 mg, PEPCID® 20 mg
35 A Randomized, Open-label, Balanced, Two-treatment, Four-period, Two-sequence, Single Dose, Fully Replicate, Crossover, Oral Bioequivalence Study of Alpha Lipoic Acid 600 mg HR Film Coated Tablets of Llko Ilac San. Ve Tic. A.S., Turkey and Thioctacid (Alpha Lipoic Acid) 600 mg HR Film Coated Tablets of Meda Pharma GmbH& CO .KG, Germany in 28 Healthy, Adult, Human Subjects Under Fasting Conditions. Completed NCT04214665 Phase 1 Alpha Lipoic acid 600 mg HR film coated tablets
36 A Phase I Study of a Novel Chemotherapeutic Regimen: Topotecan, Ifosfamide and Carboplatin (TIC) in Children and Young Adults With Solid Tumors-- A Limited Multi-Institution Study Completed NCT00502892 Phase 1 Topotecan;Ifosfamide;Carboplatin
37 An Exploratory Study of Transcranial Magnetic Stimulation (TMS) Based on Functional Magnetic Resonance Imaging (fMRI) in the Treatment of Tic Disorder Recruiting NCT04128397 Phase 1
38 A Prospective, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (Travoprost) Implant in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension Recruiting NCT04360174 Phase 1 OTX-TIC
39 Peripheral Induction of Inhibitory Brain Circuits to Treat Tourette's: Pilot Not yet recruiting NCT04731714 Phase 1
40 An Open Label, One Arm Pilot Study to Measure the Efficacy and Safety of Dysport in the Treatment of Vocal Tics in Patients With Tourette's Syndrome and Chronic Tic Disorders Unknown status NCT02187679 Abobotulinum toxin A
41 Randomized Control Trial on the Efficacy of Habit Reversal Treatment Programme in Children and Adolescents - a Comparison With Resource Activation Treatment Unknown status NCT02144870
42 Within Subject Design on the Efficacy of a Resources Activation Treatment Programme in Children and Adolescents With Tics Unknown status NCT02190370
43 A Double-blind, Randomized, Sham-controlled Study of Cranial Electrotherapy Stimulation as an Add-on Treatment for Tic Disorders in Children and Adolescents(SCATT) Unknown status NCT03705988
44 Within Subject Design on the Efficacy of Habit Reversal Treatment Programme in Children and Adolescents With Tics Unknown status NCT02190383
45 Multicentre, Randomised, Double-blinded, Placebo-controlled Trial of Efficacy of Amoxicilline/Clavulanic Acid in Patients Affected by Tic Disorder Colonized by Group A Streptococcus Unknown status NCT01860300 Amoxicillin-Potassium Clavulanate Combination;placebo
46 Tel Aviv Sourasky Medical Center Unknown status NCT02407951
47 Prevalence of Tics in Childern With Acute Deficit Hyper Activity Syndrom Unknown status NCT03817710
48 Using Transcranial Magnetic Stimulation to Reduce Tics Completed NCT01258790
49 Creating a Computerized Self-administered Version of Comprehensive Behavioral Intervention for Tics Completed NCT02413216
50 Internet-based Behaviour Therapy for Tourette's Disorder and Chronic Tic Disorder: A Feasibility Study Completed NCT02864589

Search NIH Clinical Center for Tic Disorder

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Clonazepam

Genetic Tests for Tic Disorder

Anatomical Context for Tic Disorder

MalaCards organs/tissues related to Tic Disorder:

40
Breast, Brain, Prostate, Eye, Globus Pallidus, Cortex, Colon

Publications for Tic Disorder

Articles related to Tic Disorder:

(show top 50) (show all 4715)
# Title Authors PMID Year
1
Telephone Screening of Cognitive Status (TICS) in severe COVID-19 patients: Utility in the era of social isolation. 61
33495738 2021
2
Implementation of the Mini-Child Tourette Syndrome Impairment Scale: Relationships to Symptom Severity and Treatment Decisions. 61
33124927 2021
3
Diagnostic approach to paediatric movement disorders: a clinical practice guide. 61
33150968 2021
4
Streptococcus and Tics: Another Brick in the Wall? 61
33568540 2021
5
Commentary: What is unsought will go undetected - a commentary on Rodin et al. (2020). 61
32930452 2021
6
Association of Group A Streptococcus Exposure and Exacerbations of Chronic Tic Disorders: A Multinational Prospective Cohort Study. 61
33568537 2021
7
Verteporfin induces apoptosis and reduces the stem cell-like properties in Neuroblastoma tumour-initiating cells through inhibition of the YAP/TAZ pathway. 61
33347823 2021
8
Hormonal and Subjectively Perceived Stress of the Emergency Physicians of the Airborne Rescue Service. 61
33594632 2021
9
[Personal Resources of Geriatric Nursing Staff - Results of a Cross-Sectional Study]. 61
33607696 2021
10
The New "Wholly Trinity" in the Diagnosis and Management of Inborn Errors of Immunity. 61
33551037 2021
11
Self-Rated Mentalizing Mediates the Relationship Between Stress and Coping in a Non-Clinical Sample. 61
33567977 2021
12
Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study. 61
33594741 2021
13
Why don't children in Uganda have tics? A mixed-methods study of beliefs, knowledge, and attitudes of health professionals. 61
32516519 2021
14
Internalizing and neurodevelopmental problems in young people: Educational outcomes in a large population-based cohort of twins. 61
33596506 2021
15
Low prevalence of risk drinking in adolescents and young adults with autism spectrum problems. 61
33080544 2021
16
Non-epileptic paroxysmal events in paediatric patients: A single tertiary centre study in Egypt. 61
33607445 2021
17
Evaluation of hemodynamic changes using near-infrared spectroscopy in patients with tic-related obsessive-compulsive disorder. 61
33543818 2021
18
The 5 Pillars in Tourette Syndrome Deep Brain Stimulation Patient Selection: Present and Future. 61
33593864 2021
19
Neuroimaging the emotional modulation of urge inhibition in Tourette Syndrome. 61
33317808 2021
20
Different responses of repetitive behaviours in juvenile and young adult mice to Δ9 -tetrahydrocannabinol and cannabidiol may affect decision making for Tourette syndrome. 61
33125731 2021
21
SCIRT lncRNA Blocks the Shot of Breast Cancer Cells Self-Renewal Mechanism. 61
33526468 2021
22
MYD88 signals induce tumour-initiating cell generation through the NF-κB-HIF-1α activation cascade. 61
33597599 2021
23
Paroxysmal kinesigenic dyskinesia: a diagnostic challenge. 61
33547116 2021
24
Association of Tourette Syndrome and Chronic Tic Disorder With Subsequent Risk of Alcohol- or Drug-Related Disorders, Criminal Convictions, and Death: A Population-Based Family Study. 61
33229038 2021
25
Unilateral akathisia and choreoathetosis as an unusual presentation of a frontal lobe dermoid cyst. 61
32098514 2021
26
Deep Brain Stimulation for OCD in a Patient With Comorbidities: Epilepsy, Tics, Autism, and Major Depressive Disorder. 61
33535803 2021
27
Risk of Substance Use Disorder and Its Associations With Comorbidities and Psychotropic Agents in Patients With Autism. 61
33394019 2021
28
Dexmedetomidine or Propofol for Sedation in Mechanically Ventilated Adults with Sepsis. 61
33528922 2021
29
Evaluation of Intravenous Immunoglobulin in Pediatric Acute-Onset Neuropsychiatric Syndrome. 61
33601937 2021
30
Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride. 61
32986159 2021
31
Dementia in veterans and non-veterans in England: a cross-sectional survey. 61
33410882 2021
32
Clinical features and neuropsychiatric comorbidities in pediatric patients with tic disorders: a retrospective chart review study from South Korea. 61
33413251 2021
33
Defining tic severity and tic impairment in Tourette Disorder. 61
33338735 2021
34
Text messaging as a tool to improve cancer screening programs (M-TICS Study): A randomized controlled trial protocol. 61
33481914 2021
35
A single case of tics secondary to gunshot wound. 61
32713737 2021
36
Application of 18-fluorodeoxyglucose as an indicator of symptom severity in a rat model of tic disorder following treatment with traditional Chinese medicine. 61
33273979 2021
37
Tics induced by antiepileptic drugs: a pragmatic review. 61
32804278 2021
38
STARD1 promotes NASH-driven HCC by sustaining the generation of bile acids through the alternative mitochondrial pathway. 61
33515644 2021
39
One Stone, Three Birds: pH Triggered Transformation of Aminopyronine and Iminopyronine Based Lysosome Targeting Viscosity Probe for Cancer Visualization. 61
33373187 2021
40
Contrast-Enhanced Brain Ultrasound Perfusion Metrics in the EXTra-Uterine Environment for Neonatal Development (EXTEND): Correlation With Hemodynamic Parameters. 61
33512029 2021
41
IGLL5 is correlated with tumor-infiltrating immune cells in clear cell renal cell carcinoma. 61
33449444 2021
42
Hair cortisol-a stress marker in children and adolescents with chronic tic disorders? A large European cross-sectional study. 61
33459885 2021
43
Group behavioral interventions for tics and comorbid symptoms in children with chronic tic disorders. 61
33415472 2021
44
Elevated Expression of SLC6A4 Encoding the Serotonin Transporter (SERT) in Gilles de la Tourette Syndrome. 61
33445578 2021
45
Tonic Tics in Gilles de la Tourette Syndrome. 61
33445190 2021
46
Evidence for the role of the dorsal ventral lateral posterior thalamic nucleus connectivity in deep brain stimulation for Gilles de la Tourette syndrome. 61
33045620 2021
47
Potential application of dynamic contrast enhanced ultrasound in predicting microvascular invasion of hepatocellular carcinoma. 61
33459703 2021
48
Tics in patients with encephalitis. 61
33486621 2021
49
Dll1+ quiescent tumor stem cells drive chemoresistance in breast cancer through NF-κB survival pathway. 61
33462238 2021
50
Maternal Autoimmunity and Inflammation are Associated with Childhood Tics and Obsessive-Compulsive Disorder: Transcriptomic Data show Common Enriched Innate Immune Pathways. 61
33422639 2021

Variations for Tic Disorder

Expression for Tic Disorder

Search GEO for disease gene expression data for Tic Disorder.

Pathways for Tic Disorder

Pathways related to Tic Disorder according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.17 HTR2A DRD4 DRD2
2
Show member pathways
10.29 TPH2 SLC6A3 DRD4 DRD2

GO Terms for Tic Disorder

Cellular components related to Tic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.93 SLITRK1 NRXN1 NLGN4X HTR2A DLGAP3 CNTNAP2
2 cell surface GO:0009986 9.88 SLC6A3 NRXN1 NLGN4X HSPD1 CNTNAP2
3 dendrite GO:0030425 9.83 NLGN4X HTR2A DRD4 DRD2 CNTNAP2
4 axon GO:0030424 9.77 SLC6A3 PVALB HTR2A DRD2 CNTNAP2
5 neuronal cell body GO:0043025 9.72 SLC6A3 PVALB NRXN1 HTR2A CNTNAP2
6 glutamatergic synapse GO:0098978 9.55 SLITRK1 HTR2A DRD4 DRD2 DLGAP3
7 synapse GO:0045202 9.5 SLITRK5 SLITRK1 NRXN1 NLGN4X HTR2A DRD2
8 integral component of postsynaptic membrane GO:0099055 9.43 SLC6A3 HTR2A DRD2
9 dopaminergic synapse GO:0098691 9.4 SLC6A3 DRD2
10 integral component of presynaptic membrane GO:0099056 8.92 SLC6A3 NRXN1 HTR2A DRD2

Biological processes related to Tic Disorder according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.94 SLC6A3 HTR2A HSPD1 DRD2
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.88 NRXN1 MIR24-1 HTR2A DRD2
3 cellular calcium ion homeostasis GO:0006874 9.82 HTR2A DRD4 DRD2
4 axonogenesis GO:0007409 9.81 SLITRK5 SLITRK1 DRD2
5 chemical synaptic transmission GO:0007268 9.8 SLITRK5 NRXN1 NLGN4X HTR2A DRD4
6 learning GO:0007612 9.73 NRXN1 NLGN4X CNTNAP2
7 synapse assembly GO:0007416 9.72 SLITRK1 NRXN1 DRD2
8 positive regulation of synapse assembly GO:0051965 9.7 SLITRK5 SLITRK1 NRXN1
9 dopamine receptor signaling pathway GO:0007212 9.67 DRD4 DRD2
10 temperature homeostasis GO:0001659 9.66 HTR2A DRD2
11 response to iron ion GO:0010039 9.66 SLC6A3 DRD2
12 dopamine metabolic process GO:0042417 9.65 DRD4 DRD2
13 neuron cell-cell adhesion GO:0007158 9.65 NRXN1 NLGN4X
14 response to cocaine GO:0042220 9.65 SLC6A3 HSPD1 DRD2
15 grooming behavior GO:0007625 9.63 SLITRK5 DRD2
16 positive regulation of vascular associated smooth muscle cell apoptotic process GO:1905461 9.63 MIR24-1 MIR140
17 prepulse inhibition GO:0060134 9.62 SLC6A3 DRD2
18 synaptic transmission, dopaminergic GO:0001963 9.62 DRD4 DRD2
19 presynaptic membrane assembly GO:0097105 9.61 NRXN1 NLGN4X
20 negative regulation of voltage-gated calcium channel activity GO:1901386 9.61 DRD4 DRD2
21 postsynaptic membrane assembly GO:0097104 9.6 NRXN1 NLGN4X
22 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.59 HTR2A DRD2
23 behavioral response to ethanol GO:0048149 9.58 DRD4 DRD2
24 adenohypophysis development GO:0021984 9.57 SLC6A3 DRD2
25 hyaloid vascular plexus regression GO:1990384 9.54 SLC6A3 DRD2
26 vocalization behavior GO:0071625 9.54 NRXN1 NLGN4X CNTNAP2
27 vocal learning GO:0042297 9.51 NRXN1 CNTNAP2
28 behavioral response to cocaine GO:0048148 9.5 HTR2A DRD4 DRD2
29 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.49 DRD4 DRD2
30 response to histamine GO:0034776 9.46 DRD4 DRD2
31 social behavior GO:0035176 9.46 NRXN1 NLGN4X DRD4 CNTNAP2
32 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.43 DRD4 DRD2
33 striatum development GO:0021756 9.43 SLITRK5 DRD2 CNTNAP2
34 regulation of dopamine metabolic process GO:0042053 9.13 SLC6A3 PNKD DRD4
35 adult behavior GO:0030534 9.1 SLITRK5 SLITRK1 NRXN1 NLGN4X DRD2 CNTNAP2

Molecular functions related to Tic Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex binding GO:0044877 9.65 SLC6A3 PVALB HTR2A HSPD1 DRD2
2 dopamine neurotransmitter receptor activity GO:0004952 9.16 DRD4 DRD2
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.96 DRD4 DRD2
4 dopamine binding GO:0035240 8.8 SLC6A3 DRD4 DRD2

Sources for Tic Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....